Metformin compared with placebo for high pressure in liver veins in cirrhosis
Tests metformin against placebo in people with cirrhosis and portal hypertension taking carvedilol.
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- France8 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Portal hypertension in cirrhosis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 76 people, planned
- Started
- 4 Mar 2025
- Planned end
- 1 Sept 2026
- Type of study
- Interventional
- Record updated
- 7 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cirrhosis and high blood pressure in the liver's veins (portal hypertension) who already take carvedilol. It compares metformin with a placebo (dummy pill) for 28 days.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Cirrhosis, Child-Pugh A or B. The doctor judges it likely that the HVPG (pressure gradient in the liver veins) is ≥ 12 mm Hg. The cause of cirrhosis is active, or was resolved at least 6 months ago.
- Earlier treatment
- Must take carvedilol (≥ 6,25 mg/day) at a stable dose for at least one month.
- Biomarker or test result
- Likely HVPG ≥ 12 mm Hg.
Main reasons for not taking part
- Liver cancer with a nodule > 3 cm (1.2 in) or more than 3 nodules on scans in the past 6 months
- Serum total bilirubin > 50 µmol/L
- Prothrombin ratio < 50 %
- Transaminases (liver enzymes) > 5 times the upper normal limit
- Needed fluid drained from the belly (paracentesis) at least once in the last 6 months
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age ≥ 18 years
- Absence of hepatocellular carcinoma outside at least one nodule > 3 cm in diameter, or more than 3 nodules, on ultrasound, CT-scan or MRI performed during the previous 6 months
- Written informed consent to participate in the study
- Medical insurance coverage
- For child-bearing aged women, contraception using oestroprogestative, progestative, intrauterine device, or mechanical contraception
- Diagnosis of cirrhosis based on a liver biopsy, or on clinical, biological, endoscopic, and radiological evidence
- Active cause of cirrhosis, or resolution (alcohol cessation, sustained virological response to direct-acting antiviral treatment for HCV, initiation of nucleoside/nucleotide analog treatment for HBV) for at least 6 months
- Child-Pugh A or B
- High likelihood of HVPG ≥ 12 mm Hg based on investigator’s judgement, _confer criteria in the protocole
- Treatment with carvedilol (≥ 6,25 mg/day) at a stable dose for at least one month
Who cannot take part
- Serum total bilirubin > 50 µmol/L
- Transaminases > 5 ULN
- Prothrombin ratio < 50 %
- Need for at least one paracentesis for ascites fluid evacuation in the last 6 months
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the effect of metformin versus placebo during 28 days on HVPG, in patients with cirrhosis and a HVPG ≥ 12 mm Hg already treated with carvedilol. Objectif of the ancillary study : To study the effect of metformin on postprandial changes in systemic haemodynamics and HVPG.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Effects of Metformin on hepatic venous pressure gradient in patients with cirrhosis and portal hypertension – A randomized placebo-controlled study
- Plain-language title
- Metformin compared with placebo for high pressure in liver veins in cirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 7 September 2026